Business
Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
Dosing of all patients was completed at the end of February No Serious Adverse Events (SAE’s) have been reported Phase 1 clinical initial safety and antibody
About this update from Dyadic International, Inc.
[{"type":"text","content":"Dosing of all patients was completed at the end of February No Serious Adverse Events (SAE’s) have been reported Phase 1 clinical initial safety and antibody response update expected in Q2, 2023 JUPITER, Fla., March 07, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (\"Dyadic\", \"we\", \"us\", \"our\", or the \"Company\") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today provided an update regarding its Phase 1 Clinical Trial for its DYAI-100 COVID-19 recombinant protein receptor binding domain (RBD) booster vaccine candidate. “We are pleased that patient dosing of both low and high dose groups has been completed. Thus far, the vaccine has been well tolerated with no Serious Adverse Events being reported to date,” said Mark Emalfarb, CEO of Dyadic. “While our C1 protein production platform has shown safety and efficacy in multiple animal studies for vaccines and antibodies, this is the first time a vaccine or treatment manufactured from our C1-cell protein production platform has been tested in humans for clinical safety. The DYAI-100 recombinant protein antigen COVID-19 booster vaccine is an example of our highly efficient and economical approach to the rapid manufacture of large quantities of vaccines.” Mr. Emalfarb continued, “This study is also expected to demonstrate antibody responses in humans from C1 produced antigens and the success of this trial is expected to accelerate the adoption of Dyadic’s C1-cell protein production platform for both vaccine and therapeutic candidates. We are already starting to see an increased level of interest from academia, industry, and government agencies.” About DYAI-100 DYAI-100, also known as C1-SARS-CoV-2 RBD vaccine, is a novel receptor binding domain (RBD) recombinant protein booster vaccine candidate, highly expressed in Dyadic's proprietary C1-cell protein production platform for the prevention of COVID-19. The C1-SARS-CoV-2 RBD vaccine drug product consists of the SARS-CoV-2 RBD adjuvanted with Alhydrogel 85® 2%. About DYAI-100 Phase 1 Clinical Trial Dyadic’s Phase 1 randomized, double blind, placebo-controlled trial is de...